ALCAM and colorectal carcinoma: Specific combinations of markers of stem cells and proteins reflecting the activity of β-catenin/mTOR signalling pathways, e.g., CD44/CD166 (p = 0.017), CD166/β-catenin (p = 0.036), CD44/β-catenin (p = 0.001) and CD44/CD166/β-catenin (p = 0.001), could be predictors of poor survival in stage II CRC and/or development of liver metastasis [47].